Core Insights - The Hong Kong stock market for innovative drugs is experiencing a strong rally, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising over 3% and achieving a trading volume exceeding 1.3 billion yuan yesterday and over 1 billion yuan today, bringing its total size to over 25 billion yuan [1][3]. Group 1: Market Performance - The innovative drug sector has seen significant interest, with the ETF's latest scale leading among its peers [1]. - Notable stocks within the ETF, such as Rongchang Biopharmaceutical and Zai Lab, have reported gains exceeding 6%, while others like Innovent Biologics and CSPC Pharmaceutical have also shown strong performance [4][5]. Group 2: Recent Developments - Recent collaborations in the innovative drug sector include a partnership between Fuhong Hanlin and Eisai for the commercialization of the anti-PD-1 monoclonal antibody, with an upfront payment of $75 million and potential milestone payments totaling up to $300 million [3]. - Yunding Xinyao announced the approval of Etrasimod for the treatment of moderate to severe active ulcerative colitis in China, following a $224 million deal for exclusive rights in Greater China and South Korea [3]. - Innovent Biologics has entered a strategic collaboration with Eli Lilly to advance global R&D in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3]. Group 3: Analyst Recommendations - Analysts from Kaiyuan Securities suggest increasing allocation to the innovative drug sector, highlighting the valuation attractiveness of quality stocks and the potential for significant returns from companies with strong clinical data and overseas expansion prospects [4]. - The report emphasizes the importance of focusing on innovative drugs that have shown resilience and potential for growth, particularly in the context of upcoming earnings reports in 2025 and early 2026 [6].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The commercialization of ADC (Antibody-Drug Conjugates) is accelerating, with 20 ADC drugs approved globally, and 6 of them have been in the "billion-dollar club" for two consecutive years [30][31] - The report highlights the increasing competition in the ADC sector, with approximately 60 ADC drugs currently in clinical phase 3 and application stages [30] - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [31][32] Summary by Sections Market Review - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10] - Year-to-date, the pharmaceutical index has increased by 3.28%, also outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10] Individual Stock Performance - In the A-share market, 255 out of 479 pharmaceutical stocks rose, with the top five performers being Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20] - In the Hong Kong market, 38 out of 116 pharmaceutical stocks rose, with the top performers including Yiteng Jiahe (+14%) and Kedi-B (+9.96%) [24] Industry News and Policies - The newly revised "Regulations on the Implementation of the Drug Administration Law" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization cooperation [32] - Notable industry developments include Novartis's application for Ianalumab in China and Johnson & Johnson's approval of Daratumumab injection for multiple myeloma treatment [27][28] Weekly Insights - The ADC commercialization battle has begun, with a significant increase in demand for ADC production capacity, leading to a supply-demand imbalance [30] - Major CXO companies are expanding ADC production capacity, with companies like WuXi AppTec acquiring East Yao Pharmaceutical to meet rising orders [31]

Bamboo Works 咏竹坊 专注于报道中概股新闻。用高质量的中英文 内容帮助中国企业讲好中国股事，触达全球投资者。 我们的报道也通过全球各大财经平台进行分发。日均触达200,000 人次的全球投资者。 如需咨询，请联系 info@thebambooworks.com About Us 协议约定，云顶新耀将向麦科奥特支付2亿元人民币首付款，以及最高达10.4亿元人民币的潜在监管与商业里程碑付款。中国III期临床 研究正在进行中，相关临床开发费用将由麦科奥特承担。 另据云顶新耀上周五公告，维适平获中国国家药品监督管理局批准上市，该药用于治疗对传统治疗或生物制剂应答不充分、失应答或 不耐受的中重度活动性UC成人患者。 维适平（艾曲莫德）是新一代高选择性S1P受体调节剂。云顶新耀表示，该药基于两项III期研究数据获批上市，证明其在试验过程 中"在所有主要及次要疗效终点上均达到统计学显著性和临床意义"。 受上述消息推动，云顶新耀股价在上周四、周五两个交易日内累计上涨5.5%，2026年年内涨幅随之扩大至7.2%。 云顶新耀 有限公司（1952.HK）上周四宣布与 麦科奥特 达成独家商业化许可协议，商业化后者用于治 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, particularly highlighting the high-quality development plan for traditional Chinese medicine [2][11]. Core Insights - The pharmaceutical sector's overall performance shows a slight increase, with the Shenwan Pharmaceutical and Biological Index rising by 0.14%, while the Shanghai Composite Index fell by 1.27% [3][2]. - The report emphasizes the implementation of the "High-Quality Development Implementation Plan for Traditional Chinese Medicine Industry (2026-2030)", which aims to enhance the supply chain and technological advancements in the industry [11][12]. - Key performance indicators for major drugs include significant sales growth for Eli Lilly's Tirzepatide, projected to reach $36.5 billion in 2025, and a 54% year-on-year increase in sales for the Alzheimer's drug Lecanemab [14][16]. Market Performance Summary - The Shenwan Pharmaceutical and Biological Index ranked 15th among 31 sub-industries, with various segments showing mixed performance: - Raw materials (+0.6%) - Traditional Chinese medicine (+2.6%) - Chemical preparations (-0.8%) - Blood products (-0.5%) [2][4]. - The overall valuation of the pharmaceutical sector stands at 29.6 times earnings, ranking 13th among 31 primary industries [4][2]. Recent Key Events - The report highlights several significant collaborations and licensing agreements, including: - A $1.5 billion deal between Saint Inbiotech and Genentech for RNAi therapy [17]. - A $1 billion commercialization agreement for a JAKi nasal spray by Jichuan Pharmaceutical [18]. - A $3.88 billion licensing agreement for PD-1 monoclonal antibody H drug by Fuhong Hanlin with Eisai [19] [20]. - The report also notes the IPO preparation of Brain Interface Company, which aims to innovate in neuro-scientific solutions [21]. Investment Recommendations - The report suggests focusing on companies involved in the high-quality development of traditional Chinese medicine, such as Zhaoli Pharmaceutical, Lingrui Pharmaceutical, and Huaren Jiangzhong [2][11]. - It also recommends innovative drug companies and CXO firms, including Hengrui Medicine, BeiGene, and WuXi AppTec, as potential investment opportunities [2][11].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][33]. Core Insights - The pharmaceutical sector saw a slight increase of 0.14% in the week, while the Shanghai Composite Index decreased by 1.27% [3][2]. - The report highlights the implementation of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and other departments, aiming to enhance the supply chain and technological advancements in the traditional Chinese medicine sector [11][12]. - Key pharmaceutical products such as Eli Lilly's Tirzepatide are projected to generate significant sales, with estimates of $36.5 billion in 2025, reflecting a 99% year-on-year growth for the diabetes version and a 175% growth for the weight loss version [15][17]. - The report notes active licensing and collaboration in the industry, with significant deals such as a $1.5 billion agreement between Saint's RNAi therapy and Genentech, and various other collaborations involving companies like Jichuan Pharmaceutical and Baiyunguan [18][20]. Market Performance Summary - The overall valuation of the pharmaceutical sector is reported at 29.6 times earnings, ranking 13th among 31 sectors [4][14]. - The performance of various sub-sectors includes: - Raw materials (+0.6%) - Traditional Chinese Medicine (+2.6%) - Chemical preparations (-0.8%) - Medical devices (+0.1%) [4][3]. Key Events and Developments - The report emphasizes the importance of the new plan for traditional Chinese medicine, which includes goals such as establishing 60 high-standard raw material production bases and developing 10 major traditional Chinese medicine products by 2030 [12][11]. - Notable company developments include: - Eli Lilly's projected revenue growth driven by Tirzepatide [15]. - And the announcement of significant profit forecasts from Heptares Pharmaceuticals, indicating a shift towards profitability [16]. Investment Recommendations - The report suggests focusing on domestic companies related to traditional Chinese medicine, such as Zoli Pharmaceutical and Yunnan Baiyao, as well as innovative drug companies like Heng Rui Pharmaceutical and Bai Jie Shen Zhou [2][18].

Market Overview - The Hong Kong stock market opened higher on February 9, with the Hang Seng Index rising by 1.59% to 26,982.49 points, the Hang Seng Tech Index up by 1.9% to 5,447.63 points, and the National Enterprises Index increasing by 1.54% to 9,170.57 points. The Red Chip Index rose by 0.89% to 4,399.55 points [1] - Last week, the Hang Seng Index recorded a significant decline of 3.02%, while the National Enterprises Index fell by 3.07%, and the Hang Seng Tech Index dropped by 6.51% [1] Company Performance and Dynamics - Beijing Capital International Airport Co. (00694.HK) issued a profit warning, expecting a net loss of 600 million to 760 million yuan for 2025, which represents a year-on-year reduction in losses of approximately 45.3% to 56.8%. This improvement is attributed to the recovery in aviation market demand and enhanced cost control [2] - Times Electric (03898.HK) reported preliminary results indicating total revenue of approximately 28.761 billion yuan for 2025, a year-on-year increase of 15.46%, with a net profit of about 4.105 billion yuan, up by 10.88% [2] - Power sector stocks saw a general increase, with Datang Environment (01272.HK) expecting a pre-tax profit of 700 million to 710 million yuan for 2025. Datang New Energy (01798.HK) reported a power generation of 3.272 million MWh in January, a year-on-year increase of 6.69%, while Longyuan Power (00916.HK) generated 7.1627 million MWh, up by 12.05%, with solar power generation increasing by 42.25% [2] Real Estate Sales - Yuexiu Property (00123.HK) reported a contract sales amount of 4.201 billion yuan in January, a year-on-year decrease of 36.4%. Poly Real Estate (01238.HK) had sales of 470 million yuan, down by 31.98%. In contrast, Greenland Hong Kong (00337.HK) saw a significant increase in sales to 508 million yuan, up by 287.79% year-on-year [3] Pharmaceutical and Technology Developments - CloudTop New Medicine (01952) received approval for a new drug application for the treatment of ulcerative colitis. Kelun-Biotech (06990.HK) received approval for the fourth indication of its core product TROP2 ADC. Heng Rui Medicine (01276.HK) had its HRS-4642 injection included in the breakthrough therapy list [4] - ZTE Corporation (00763.HK) plans to invest 200 million yuan to subscribe to shares of the Guangdong-Hong Kong-Macao fund, focusing on hard technology sectors [4] Stock Buybacks and Financing - Kingsoft (03888.HK) repurchased 1.1142 million shares for approximately 29.9994 million HKD. Geely Automobile (00175.HK) repurchased 166.5 million shares for about 27.1612 million HKD. October Rice Field (09676.HK) repurchased 78 million shares for approximately 7.3357 million HKD. China Galaxy (06881.HK) completed the issuance of 6 billion yuan in corporate bonds [5] Institutional Perspectives - According to浦银国际, the market is expected to maintain a volatile trend in the short term, with a rotation of style. The inflow of incremental funds is slowing before the Spring Festival, and external liquidity is affected by geopolitical uncertainties and Trump’s policies, limiting the expansion space for Hong Kong stock valuations [6] - 广发证券 noted that historical data shows an 82% probability of the Hang Seng Index rising in the three days before the Spring Festival, although there is no significant calendar effect afterward. The current situation differs due to changes in Hong Kong stock pricing logic and increased correlation with A-shares, suggesting a potential passive follow-up increase in Hong Kong stocks [7]

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

中证报中证网讯(记者李梦扬)2月6日，云顶新耀公告，中国国家药品监督管理局(NMPA)已批准维适平 的新药上市申请，在中国用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活 动性溃疡性结肠炎(UC)成人患者。 云顶新耀首席执行官罗永庆表示，此次维适平在中国的获批，填补了中重度溃疡性结肠炎治疗领域的重 要空白，为以深度黏膜愈合为目标的创新口服治疗提供了新选择。公司将加快推进维适平的商业化进 程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多患者受益。 云顶新耀董事会主席吴以芳表示："自身免疫性疾病在全球范围内对患者造成长期而深远的影响，在中 国乃至全球范围内，仍存在大量尚未满足的临床需求。维适平的获批不仅体现了创新疗法在溃疡性结肠 炎治疗中的临床价值，也彰显公司坚持以国际研发标准推进创新药物发展的长期战略。我们期待通过持 续拓展全球化布局，让更多患者受益于高质量、具有突破性的治疗选择。" 此次维适平的获批，云顶新耀方面表示，标志着公司在自身免疫疾病领域实现突破，商业化产品矩阵进 一步丰富。经过多年深耕，公司已打造了一套基于科学及商业洞察驱动的准入、医学、市场、销售 ...

2026年2月6日，港股创新药企云顶新耀(01952)宣布，其自身免疫性疾病领域的核心产品维适平 (精氨酸 艾曲莫德片, VELSIPITY )获得中国国家药品监督管理局(NMPA)批准上市，用于治疗对传统治疗或生物 制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎(UC)成人患者。 国际权威指南一线推荐 成熟商业化平台将加速维适平 市场落地 作为新一代高选择性S1P受体调节剂，维适平 每日一次口服，可实现快速起效和强效深度黏膜愈合，并 具有良好的安全性特征，具备最佳药物(best-in-disease)潜质，为成人溃疡性结肠炎患者提供新的一线治 疗选择，其商业化前景获业内广泛看好。据预测，其销售峰值或达50亿元，将成为云顶新耀继肾病领域 耐赋康 后的又一核心单品，此举也预示着其商业化版图有望迎来新一轮高速增长。 云顶新耀首席执行官罗永庆对此表示，此次维适平 在中国的获批，填补了中重度溃疡性结肠炎治疗领 域的重要空白，并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平 的商业化进程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多 患者受益。 维 ...

Company News - Beijing Capital International Airport Co., Ltd. (00694.HK) expects a net loss of approximately RMB 6.0 billion to RMB 7.6 billion in 2025, a year-on-year reduction of about 45.3% to 56.8%, benefiting from the recovery in aviation market demand and enhanced cost control [1] - Times Electric (03898.HK) anticipates total operating revenue of approximately RMB 28.761 billion in 2025, a year-on-year increase of 15.46%, with a net profit of about RMB 4.105 billion, up 10.88% year-on-year [1] - Hong Kong Tong Holdings (00032.HK) issued a profit warning, expecting a year-on-year increase in profit attributable to shareholders to approximately HKD 660 million for the fiscal year 2025 [1] - Datang Environment Industry Group (01272.HK) issued a profit warning, expecting pre-tax profit to rise to approximately RMB 700 million to RMB 710 million in 2025 [1] Power Generation - Datang New Energy (01798.HK) completed power generation of 3.272 million MWh in January, a year-on-year increase of 6.69% [2] - Longyuan Power (00916.HK) achieved power generation of 7.1627 million MWh in January, a year-on-year growth of 12.05%, with wind power generation increasing by 8.11% and solar power generation rising by 42.25% [2] - Jiangshan Holdings (00295.HK) reported total power generation of approximately 18.3 thousand MWh in January, a year-on-year decrease of 22.13% [4] Real Estate - Yuexiu Property (00123.HK) reported contract sales of approximately RMB 4.201 billion in January, a year-on-year decline of about 36.4% [2] - Poly Real Estate (01238.HK) recorded total contract sales of approximately RMB 470 million in January, a year-on-year decrease of 31.98% [2] - Greenland Hong Kong (00337.HK) reported contract sales of approximately RMB 508 million in January, a year-on-year increase of about 287.79% [3] Other Developments - CloudTop New Drug (01952) received approval for the new drug application of Vedolizumab for treating moderate to severe ulcerative colitis in adults in China [4] - Zhonghang Science and Technology (02357.HK) plans to invest RMB 58 million to acquire a 10% stake in Zhonghang Jierui [4] - Kelun-Biotech (06990.HK) received approval for the fourth indication of its core product TROP2ADC for treating 2L+ HR+/HER2- breast cancer [4] Financing and Buyback Activities - Kingsoft Corporation (03888.HK) repurchased approximately 1.1142 million shares for about HKD 29.9994 million, with repurchase prices ranging from HKD 26.8 to HKD 27 [7] - Geely Automobile (00175.HK) repurchased approximately 1.665 million shares for about HKD 27.1612 million, with repurchase prices between HKD 15.94 and HKD 16.44 [7] - October Rice Field (09676.HK) repurchased 780,000 shares for approximately HKD 7.3357 million, with repurchase prices between HKD 9.3 and HKD 9.46 [7] - China Galaxy (06881.HK) completed the issuance of corporate bonds totaling RMB 6 billion [7]